Dilemmas, Confusion, and Misconceptions Related to Small Airways Directed Therapy

Chest

Volumn 151, Issue 6, 2017, Pages 1345-1355

  Lavorini, Federico ^a   Pedersen, Søren ^b   Usmani, Omar S ^c   Barnes, P J ^d   Corbetta, L ^d   Corrigan, C J ^d   Chawes, B L ^d   Dekhuijzen, P N R ^d   Hausen, T ^d   Lavorini, F ^d   Levy, M L ^d   Pedersen, S ^d   Roche, N ^d   Sanchis, J ^d   Usmani, O S ^d   Vincken, W ^d  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d NONE

Author keywords

aerosols; asthma; COPD; inhalers; small airways; small particles

Indexed keywords

BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BRONCHODILATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; HYDROCORTISONE; PLACEBO; SALBUTAMOL; BECLOMETASONE; DRUG COMBINATION; FLUOCINOLONE ACETONIDE; FORMOTEROL FUMARATE; GLUCOCORTICOID; PREGNANE DERIVATIVE;

AEROSOL; AIRWAY; ASTHMA; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISPERSION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRY POWDER INHALER; DYSPHONIA; EXHALATION; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION SPACER; METERED DOSE INHALER; PARTICLE SIZE; PRIORITY JOURNAL; RESPIRATORY THERAPEUTIC DEVICE; REVIEW; SIDE EFFECT; SMALL AIRWAY; SMALL AIRWAY DISEASE; SOFT MIST INHALER; VALVED HOLDING CHAMBER; ANALOGS AND DERIVATIVES; BRONCHIOLE; DISEASE MANAGEMENT; DRUG COMBINATION; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; PATHOPHYSIOLOGY; PRESSURE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ASTHMA; BECLOMETHASONE; BRONCHIOLES; BRONCHODILATOR AGENTS; DISEASE MANAGEMENT; DRUG COMBINATIONS; DRY POWDER INHALERS; EQUIPMENT DESIGN; FLUOCINOLONE ACETONIDE; FORMOTEROL FUMARATE; GLUCOCORTICOIDS; HUMANS; INHALATION SPACERS; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PREGNENEDIONES; PRESSURE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85020844174     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.07.035     Document Type: Review

References (81)

1. Darquenne, C., Fleming, J.S., Katz, I., et al. Bridging the gap between science and clinical efficacy: physiology, imaging and modelling of aerosol in the lung. J Aerosol Med Pulm Drug Deliv 29:2 (2016), 1–19.
2. Weibel, E.R., Morphometry of the Human Lung. 1963, Springer-Verlag, Berlin, Germany, p4–9.
3. Hogg, J.C., Chu, F., Utokaparch, S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:26 (2004), 2645–2653.
4. Hamid, Q., Song, Y., Kotsimbos, T.C., et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 100:1 (1997), 44–51.
5. Yanai, M., Sekizawa, K., Ohrui, T., Sasaki, H., Takishima, T., Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 72:3 (1992), 1016–1023.
6. in't Veen, J.C., Beekman, A.J., Bel, E.H., Sterk, P.J., Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 161:6 (2000), 1902–1906.
7. Scichilone, N., Battaglia, S., Taormina, S., Modica, V., Pozzecco, E., Bellia, V., Alveolar nitric oxide and asthma control in mild untreated asthma. J Allergy Clin Immunol 131:6 (2013), 1513–1517.
8. Wenzel, S.E., Asthma: defining of the persistent adult phenotypes. Lancet 368:9537 (2006), 804–813.
9. Kraft, M., Djukanovic, R., Wilson, S., Holgate, S.T., Martin, R.J., Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 154:5 (1996), 1505–1510.
10. Kraft, M., Pak, J., Martin, R.J., Kaminsky, D., Irvin, C.G., Distal lung dysfunction at night in nocturnal asthma. Am J Respir Crit Care Med 163:7 (2001), 1551–1556.
11. Kaminsky, D.A., Irvin, C.G., Gurka, D.A., et al. Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. Am J Respir Crit Care Med 152:6 pt 1 (1995), 1784–1790.
12. D'Amato, G., Liccardi, G., D'Amato, M., Cazzola, M., Outdoor air pollution climatic changes and allergic bronchial asthma. Eur Respir J 20:3 (2002), 763–776.
13. Usmani, O.S., Small airways dysfunction in asthma: evaluation and management to improve asthma control. Allergy Asthma Immunol Res 6:5 (2014), 376–388.
14. Usmani, O.S., Small-airway disease in asthma: pharmacological considerations. Curr Opin Pulm Med 21:1 (2015), 55–67.
15. Usmani, O.S., Treating the small airways. Respiration 84:6 (2012), 441–453.
16. Chapman, K.R., Fogarty, C.M., Peckitt, C., et al. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. Int J Obstruct Pulmon Dis 6 (2011), 353–363.
17. Colthorpe, P., Voshaar, T., Kieckbusch, T., Cuoghi, E., Jauernig, J., Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess 2:1 (2013), 11–16.
18. Lock DJ, Watkins A, Munro A. DPI performance modelling using an inhalation simulator and oropharyngeal model: a more patient-relevant approach for device development. Paper presented at: Drug Delivery to the Lungs DDL25 Conference; December 10, 2014; Edinburgh, UK.
19. Lavorini, F., Fontana, G.A., Usmani, O.S., New inhaler devices; the good, the bad and the ugly. Respiration 88:1 (2014), 3–15.
20. Labiris, N.R., Dolovich, M.B., Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:6 (2003), 588–599.
21. Corradi, M., Chrystyn, H., Cosio, B.G., et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Exp Opin Drug Deliv 11:9 (2014), 1497–1506.
22. Dalby, R.N., Eicher, J., Zierenberg, B., Development of Respimat Soft Mist inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl) 4 (2011), 145–155.
23. Hoshino, M., Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int 59:1 (2010), 59–66.
24. Huchon, G., Magnussen, H., Chuchalin, A., et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 103:1 (2009), 41–49.
25. Papi, A., Paggiaro, P., Nicolini, G., et al., and the ICAT SE study group. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 62:10 (2007), 1182–1188.
26. Postma, D.S., Roche, N., Colice, G., et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis 9 (2014), 1163–1186.
27. de Boer, A.H., Gjaltema, D., Hagedoorn, P., Frijlink, H.W., Can ‘extrafine’ dry powder aerosols improve lung deposition?. Eur J Pharm Biopharm 96 (2015), 143–151.
28. Chrystyn, H., Price, D., Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J 18:4 (2009), 243–249.
29. Mitchell, J., Newman, S., Chan, H.K., In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. AAPS PharmSciTech, 8(4), 2007, E110.
30. Laube, B., Janssens, H.M., de Jongh, F.H., et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 37:6 (2011), 1308–1331.
31. Leach, C.L., Davidson, P.J., Hasselquist, B.E., Boudreau, R.J., Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 122:2 (2002), 510–516.
32. Agertoft, L., Laulund, L.W., Harrison, L.I., Pedersen, S., Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Pediatr Pulmonol 35:3 (2003), 192–199.
33. Leach, C.L., Davidson, P.J., Boudreau, R.J., Improved airway targeting with the CFC-free HFA beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 12:6 (1998), 1346–1353.
34. Zanen, P., Laube, B.L., Targeting the lungs with therapeutic aerosols. Bisgaard, H., O'Callaghan, C., Smaldone, G., (eds.) Drug Delivery to the Lungs, 2001, Marcel Dekker, New York, NY, 211–261.
35. Usmani, O.S., Biddiscombe, M.F., Nightingale, J.A., Underwood, S.R., Barnes, P.J., Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol (1985) 95:5 (2003), 2106–2112.
36. Usmani, O.S., Biddiscombe, M.F., Barnes, P.J., Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 172:12 (2005), 1497–1504.
37. Zanen, P., Go, L.T., Lammers, J.W., Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51:10 (1996), 977–980.
38. Borrill, Z.L., Houghton, C.M., Tal-Singer, R., et al. The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol 65:2 (2008), 244–252.
39. Al-Bazzaz, F.J., Single-breath nitrogen washout: effects of alterations of lung volumes and elastic recoil. Chest 76:1 (1979), 83–88.
40. Bourdin, A., Paganin, F., Préfaut, C., Kieseler, D., Godard, P., Chanez, P., Nitrogen washout slope in poorly controlled asthma. Allergy 61:1 (2006), 85–89.
41. Leach, C.L., Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 104:6 (1999), S250–S252.
42. Leach, C.L., Bethke, T.D., Boudreau, R.J., et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med 19:2 (2006), 117–126.
43. Newman, S., Salmon, A., Nave, R., Drollmann, A., High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 100:3 (2006), 375–384.
44. de Vries, T.W., Rottier, B.L., Gjaltema, D., Hagedoorn, P., Frijlink, H.W., de Boer, A.H., Comparative in vitro evaluation of four corticosteroid metered dose inhalers: consistency of delivered dose and particle size distribution. Respir Med 103:8 (2009), 1167–1173.
45. Zierenberg, B., Optimizing the in vitro performance of Respimat. J Aerosol Med 12:suppl 1 (1999), S19–S24.
46. Pitcairn, G., Reader, S., Pavia, D., Newman, S., Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 18:3 (2005), 264–272.
47. Nicolini, G., Scichilone, N., Bizzi, A., et al. Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations. Ther Clin Risk Manag 4:5 (2008), 855–864.
48. Leach, C.L., Kuehl, P.J., Chand, R., Ketai, L., Norenberg, J.P., McDonald, J.D., Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol 108:3 (2012), 195–200.
49. Chrystyn, H., Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol 51:4 (2001), 289–299.
50. Lipworth, B.J., Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 42:6 (1996), 697–705.
51. Bateman, E.D., Linnhof, A.E., Homik, L., et al. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 21:2 (2008), 264–275.
52. Derom, E., Van De Velde, V., Marissens, S., et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5’monophosphate in asthmatic patients. Pulm Pharmacol Ther 18:5 (2005), 328–336.
53. Derom, E., Louis, R., Tiesler, C., Engelstätter, R., Kaufman, J.M., Joos, G.F., Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. Eur Respir J 33:6 (2009), 1277–1286.
54. Gerrity, T.R., Lee, P.S., Hass, F.J., Marinelli, A., Werner, P., Lourenço, R.V., Calculated deposition of inhaled particles in the airway generations of normal subjects. J Appl Physiol 47:4 (1979), 867–873.
55. Heyder, J., Assessment of airway geometry with inert aerosols. J Aerosol Sci 2 (1989), 89–97.
56. Warren, S., Taylor, G., Smith, J., Buck, H., Parry-Billings, M., Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique. J Aerosol Med 15:1 (2002), 15–25.
57. Usmani, O.S., Barnes, P.J., Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med 44:2 (2012), 146–156.
58. Scichilone, N., Contoli, M., Paleari, D., et al. Assessing and accessing the small airways: implications for asthma management. Pulm Pharmacol Ther 26:2 (2013), 172–179.
59. Kelly, H.W., Ultrafine-particle inhalers, the Holy Grail of inhaled corticosteroid therapy, or not!. J Allergy Clin Immunol Pract 3:5 (2015), 732–733.
60. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma—Full Report No.: 07-4051. 2007, National Heart, Lung, and Blood Institute, Bethesda, MD.
61. Roche, N., Reddel, H.K., Agusti, A., Bateman, E.D., et al., and the Respiratory Effectiveness Group. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med 1:10 (2013), e29–e30.
62. Herland, K., Akselsen, J.P., Skjønsberg, O.H., Bjermer, L., How representative are clinical study patients with asthma or COPD for a larger ‘real life’ population of patients with obstructive lung disease?. Respir Med 99:1 (2005), 11–19.
63. van Aalderen, W.M., Grigg, J., Guilbert, T.W., et al. Small-particle inhaled corticosteroid as first-line or step-up controller therapy in childhood asthma. J Allergy Clin Immunol Pract, 3(5), 2015 721.e16-731.e16.
64. VandenBurgt, J.A., Busse, W.W., Martin, R.J., Szefler, S.J., Donnell, D., Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 106:6 (2000), 1209–1226.
65. Thompson, P.J., Davies, R.J., Young, W.F., et al. Safety of hydrofluoalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med 92:suppl A (1998), 33–39.
66. Singh, D., Piccinno, A., Borrill, Z., et al. Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. Pulm Pharmacol Ther 21:3 (2008), 551–557.
67. Busse, W.W., Brazinsky, S., Jacobson, K., et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 104:6 (1999), 1215–1222.
68. Davies, R.J., Stampone, P., O'Connor, B.J., Hydrofluroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 92:suppl A (1998), 23–31.
69. van Schayck, C.P., Donnell, D., The efficacy and safety of QVAR (hydrofluoroalkane-beclomethasone dipropionate extrafine aerosol) in asthma (part I): an update of clinical experience in adults. Int J Clin Pract 58:7 (2004), 678–688.
70. Papi, A., Paggiaro, P.L., Nicolini, G., et al. Beclomethasone/formoterol vs. budesonide/formoterol combination therapy in asthma. Eur Respir J 29 (2007), 682–689.
71. Bousquet, J., Poli, G., Acerbi, D., Monno, R., Ramael, S., Nollevaux, F., Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclomethasone dipropionate/formoterol fixed combination. Clin Pharmacokinet 48:6 (2009), 347–358.
72. Ohbayashi, H., Adachi, M., Hydrofluoroalkane-beclomethasone dipropionate effectively improves airway eosinophilic inflammation including the distal airways of patients with mild to moderate persistent asthma as compared with fluticasone propionate in a randomized open double-cross study. Allergol Int 57:3 (2008), 1–9.
73. Lavorini, F., Fontana, G.A., Targeting drugs to the airways: the role of spacer devices. Expert Opin Drug Deliv 6:1 (2009), 91–102.
74. Nikander, K., Nicholls, C., Denyer, J., Pritchard, J., The evolution of spacers and valved holding chambers. J Aerosol Med Pulm Drug Deliv 27:suppl 1 (2014), S-4–S-23.
75. Roller, C.M., Zhang, G., Troedson, R.G., Leach, C.L., Le Souëf, P.N., Devadason, S.G., Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children. Eur Respir J 29:2 (2007), 299–306.
76. Berger, W.E., Tashkin, D.P., Flunisolide hydrofluoroalkane with integrated spacer for treating asthma: an updated review. Allergy Asthma Proc 36:2 (2015), 105–115.
77. Singh, D., Collarini, S., Poli, G., Acerbi, D., Amadasi, A., Rusca, A., Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclomethasone dipropionate/formoterol pMDI. Br J Clin Pharmacol 72:6 (2011), 932–939.
78. Kuna, P., Govoni, M., Lucci, G., Scuri, M., Acerbi, D., Stelmach, I., Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclomethasone dipropionate/formoterol fumarate in adolescent asthma. Br J Clin Pharmacol 80:3 (2015), 569–580.
79. Perez, T., Is it really time to look at distal airways to improve asthma phenotyping and treatment. Eur Respir J 38:3 (2011), 1252–1254.
80. Lipworth, B., Targeting the small airways asthma phenotype: if we can reach it, should we treat it?. Ann Allergy Asthma Immunol 110:4 (2013), 233–239.
81. Kelly, H.W., Alveolar nitric oxide concentration, small airways inflammation, and targeted asthma therapy: are we there yet?. J Allergy Clin Immunol 126:4 (2010), 736–737.